Assembly Biosciences Current Ratio 2010-2018 | ASMB

Assembly Biosciences current ratio from 2010 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Assembly Biosciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $0.24B $0.02B 16.42
2018-06-30 $0.10B $0.01B 7.43
2018-03-31 $0.11B $0.01B 9.30
2017-12-31 $0.12B $0.01B 9.13
2017-09-30 $0.07B $0.01B 5.62
2017-06-30 $0.08B $0.01B 6.48
2017-03-31 $0.09B $0.01B 8.42
2016-12-31 $0.05B $0.01B 7.52
2016-09-30 $0.06B $0.01B 7.92
2016-06-30 $0.06B $0.01B 12.71
2016-03-31 $0.06B $0.00B 16.56
2015-12-31 $0.07B $0.00B 20.09
2015-09-30 $0.07B $0.00B 25.08
2015-06-30 $0.07B $0.00B 31.85
2015-03-31 $0.10B $0.00B 45.26
2014-12-31 $0.03B $0.00B 27.72
2014-09-30 $0.02B $0.00B 17.24
2014-06-30 $0.02B $0.00B 14.80
2014-03-31 $0.02B $0.00B 16.34
2013-12-31 $0.03B $0.00B 10.28
2013-09-30 $0.03B $0.00B 13.96
2013-06-30 $0.03B $0.00B 13.02
2013-03-31 $0.04B $0.00B 18.77
2012-12-31 $0.02B $0.00B 7.49
2012-09-30 $0.02B $0.00B 8.83
2012-06-30 $0.03B $0.00B 8.55
2012-03-31 $0.03B $0.00B 8.15
2011-12-31 $0.04B $0.00B 14.74
2011-09-30 $0.05B $0.00B 45.11
2011-06-30 $0.01B $0.00B 14.89
2011-03-31 $0.01B $0.00B 45.43
2010-12-31 $0.02B $0.00B 8.48
2010-09-30 $0.00B $0.00B 0.00
2010-06-30 $0.00B $0.00B 0.00
2010-03-31 $0.00B $0.00B 0.00
2009-12-31 $0.00B $0.01B 0.01
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.541B $0.009B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $46.676B 8.40
Teva Pharmaceutical Industries (TEVA) Israel $17.694B 6.11
Mylan (MYL) United Kingdom $16.304B 6.71
Bausch Health Cos (BHC) Canada $8.412B 5.98
Dr Reddy's Laboratories (RDY) India $5.939B 23.69
Supernus Pharmaceuticals (SUPN) United States $1.968B 18.64
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.768B 2.95
Amphastar Pharmaceuticals (AMPH) United States $1.134B 123.05
Homology Medicines (FIXX) United States $0.930B 0.00
CymaBay Therapeutics (CBAY) United States $0.593B 0.00
Akorn (AKRX) United States $0.507B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.402B 0.00
Voyager Therapeutics (VYGR) United States $0.355B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.307B 0.00
Sol-Gel Technologies (SLGL) Israel $0.122B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.086B 0.00
Teligent (TLGT) United States $0.077B 0.00
Acasti Pharma (ACST) Canada $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.054B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
China Pharma Holdings (CPHI) China $0.012B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.004B 0.00